Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

FDA’s approval Friday of Rybelsus, the first oral GLP-1R agonist for diabetes, brings across the finish line a critical drug for Novo Nordisk’s growth strategy after the company prioritized best-in-class R&D three

Read the full 328 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE